# Diffuse astrocytoma, AYA-type, frequently MAPK-altered: report of 45 patients

**Authors:** Omkar Singh, Christopher Dampier, Zied Abdullaev, Karen Dazelle, Hye-Jung Chung, Kyle Conway, Sandra Camelo-Piragua, Stewart Neill, Daniel Brown, James Stephen Nix, Caterina Giannini, Robert Macaulay, Daniel Marker, John Skaugen, Scott Kulich, Han Lee, Orwa Aboud, Peter Pytel, Ewa Borys, Arie Perry, Laila Naqib-Osman, Igor Lima Fernandes, Qinwen Mao, Mouied Alashari, Cheddhi Thomas, Jeffrey Helgager, Maria A. Gubbiotti, John Newman, Nishant Tiwari, Patrick J. Cimino, Martha Quezado, Kenneth D. Aldape, MacLean P. Nasrallah

PMC · DOI: 10.1007/s00401-025-02873-8 · Acta Neuropathologica · 2025-04-09

## TL;DR

This study identifies a new type of brain tumor in young adults with specific genetic changes and distinct features, suggesting a new classification called diffuse astrocytoma, AYA-type.

## Contribution

The paper introduces a novel molecular subtype of glioma, diffuse astrocytoma, AYA-type, characterized by MAPK pathway alterations and distinct epigenetic features.

## Key findings

- Tumors show high rates of CDKN2A/2B deletion, PDGFRA amplification, and BRAF alterations.
- DAYA tumors are distinct from other gliomas in the WHO classification based on epigenetics and molecular features.
- Outcomes vary based on histologic grade and molecular features, supporting individualized grading for treatment decisions.

## Abstract

A putative molecular subtype of IDH-wildtype diffuse glioma with recurrent MAPK pathway alterations has recently been reported. By dimensionality reduction analysis of genome-wide methylation profiling, these tumors form a distinct methylation cluster of gliomas. Characterization of 47 tumors from 45 patients reveals that these gliomas are predominantly supratentorial in young adults, are highly infiltrative, and harbor mitogen-activated protein kinase (MAPK) pathway alterations with high rates of CDKN2A/2B deletion, PDGFRA amplification, MYCN amplification, NF1 variants, and BRAF alterations. The tumors’ epigenetics are distinct from other adult and pediatric gliomas in the 2021 World Health Organization (WHO) classification. The histology of the gliomas most often demonstrates high-grade astrocytic features, but can be variable from tumor to tumor, as well as fall into a spectrum of histologic grades. Outcomes show considerable variability based on histologic grade and molecular features, supporting grading within this group of tumors to ensure optimal care choices on an individual patient basis. These unifying epigenetic, sequencing, and infiltrative astrocytic features allow the tumors to be considered diffuse astrocytoma, adolescent, and young adult-type, with MAPK alterations (DAYA).

The online version contains supplementary material available at 10.1007/s00401-025-02873-8.

## Linked entities

- **Genes:** CDKN2A (cyclin dependent kinase inhibitor 2A) [NCBI Gene 1029], CDKN2B (cyclin dependent kinase inhibitor 2B) [NCBI Gene 1030], PDGFRA (platelet derived growth factor receptor alpha) [NCBI Gene 5156], MYCN (MYCN proto-oncogene, bHLH transcription factor) [NCBI Gene 4613], NF1 (neurofibromin 1) [NCBI Gene 4763], BRAF (B-Raf proto-oncogene, serine/threonine kinase) [NCBI Gene 673]

## Full-text entities

- **Genes:** MYCN (MYCN proto-oncogene, bHLH transcription factor) [NCBI Gene 4613] {aka FGLDS1, MODED, MPAPA, MYCNsORF, MYCNsPEP, N-myc}, PDGFRA (platelet derived growth factor receptor alpha) [NCBI Gene 5156] {aka CD140A, PDGFR-2, PDGFR2}, IDH1 (isocitrate dehydrogenase (NADP(+)) 1) [NCBI Gene 3417] {aka HEL-216, HEL-S-26, IDCD, IDH, IDP, IDPC}, BRAF (B-Raf proto-oncogene, serine/threonine kinase) [NCBI Gene 673] {aka B-RAF1, B-raf, BRAF-1, BRAF1, NS7, RAFB1}, NF1 (neurofibromin 1) [NCBI Gene 4763] {aka NFNS, VRNF, WSS}
- **Diseases:** tumor (MESH:D009369), Diffuse astrocytoma (MESH:D001254), diffuse glioma (MESH:D005910)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11982118/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11982118/full.md

## References

2 references — full list in the complete paper: https://tomesphere.com/paper/PMC11982118/full.md

---
Source: https://tomesphere.com/paper/PMC11982118